News

Discover how Prithwiraj Maitra, PhD, advances skin care innovation with exosomes, emphasizing scientific validation and ingredient transparency in cosmetic formulations.

From acne to psoriasis, nutrition influences disease severity, treatment response, and patient quality of life.

Explore innovative acne management strategies from James Del Rosso, DO, focusing on personalized treatments and patient education for effective results in diverse cases.

Phio Pharmaceuticals reveals promising results for PH-762, a novel siRNA therapy targeting skin cancer, showcasing effective tumor clearance and safety.

New findings from LEO Pharma reveal chronic hand eczema affects 1 in 10 adults, highlighting the need for improved recognition and management in dermatology.

Advances in atopic dermatitis research could bring longer-lasting biologics and improved treatment adherence.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

In case you missed it, this week we had news about upadacitinib for vitiligo, the commercial release of roflumilast for pediatric AD, a recap of the top pearls at Fall Clinical 2025, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover the latest advancements in atopic dermatitis treatment and patient advocacy during Eczema Awareness Month, shaping future care and quality of life.

UCB reveals three-year data on bimekizumab, showcasing significant pain relief and lesion resolution in hidradenitis suppurativa patients at the 2025 SHSA.

Christopher Bunick, MD, PhD, emphasizes how dermatologists can improve outcomes through vigilant skin exams and collaborative care with oncology teams.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Discover the latest advancements in CSU therapy, including Gil Yosipovitch's insights on barzolvolimab's promising results and its potential impact on patient care.

Onco-dermatology enhances patient care and quality of life by addressing skin toxicities in breast cancer treatments through expert management and collaboration.

Christopher Bunick, MD, PhD, urged clinicians to move beyond therapeutic inertia and transition patients to advanced systemic therapies.

CURE spoke with experts about possible dermatologic adverse effects faced by patients with breast cancer.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.

Arcutis has expanded roflumilast cream in the US, a steroid-free treatment for mild to moderate AD in young children.

Updated FDA policies eliminate many comparative efficacy trials, reducing biosimilar development time and cost by relying more on analytical testing.

La-Urshalar Brock, FNP-BC, CNM, describes tactics for managing dermatologic AEs in patients with breast cancer as part of a multidisciplinary care team.

Learn more about the in-depth topics covered in the October 2025 print issue of Dermatology Times.

Stephanie Alvarez, marketing director of Cognivia, details her experience with psoriasis and why she believes clinical trials should reflect more real-world patients and scenarios.

Avalo Therapeutics completes enrollment in the LOTUS trial for AVTX-009, targeting hidradenitis suppurativa with promising IL-1β inhibition.

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Pennsylvania Dermatology Physician Assistants (PDPA) Keystone Dermatology Conference in Philadelphia, Pennsylvania.

At Fall Clinical 2025, Andrew Alexis, MD, reviewed topical, oral, and procedural interventions with patients with melasma and hyperpigmentation, especially in patients with skin of color.

In 2 replicate phase 3 trials, once-daily upadacitinib 15 mg significantly improved total and facial repigmentation in adults and adolescents with non-segmental vitiligo, with a safety profile consistent with prior indications.

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.